Birk Venture
Birk Venture is a venture capital firm based in Oslo, Norway, founded in 2010. The firm specializes in early-stage investments in small and startup companies within the life science sector, with a particular emphasis on pharmaceuticals, biotechnology, diagnostics, medical devices, and consumer health. Birk Venture focuses on unique technologies and targets both public and private companies that demonstrate the potential for public listing within one to two years. Additionally, the firm has the capacity to co-invest with other firms to enhance its capital resources.
Zelluna Immunotherapy AS develops T-cell receptor (TCR) therapies targeting cancer antigens. The company was founded in 2016 and is based in Oslo, Norway.
Targovax ASA is a clinical-stage immuno-oncology company based in Oslo, Norway, focused on developing oncolytic viruses and neoantigen cancer vaccines to treat challenging solid tumors. Its lead product, ONCOS-102, is currently undergoing Phase I/II clinical trials for various cancers, including mesothelioma, melanoma, peritoneal disease, and prostate cancer. Additionally, Targovax is advancing TG01, a cancer vaccine in Phase I/II trials for resectable pancreatic cancer, which aims to activate the immune system to target specific RAS mutations in cancer cells. The company collaborates with notable organizations, including Cancer Research Institute, Ludwig Cancer Research, and AstraZeneca, to enhance the development of its therapies. Targovax's innovative approach aims to induce robust immune responses by leveraging both helper and cytotoxic T-cell mechanisms, demonstrating potential for improved patient survival and favorable tolerability profiles. Established in 2010 by inventors from the Radium Hospital Research Foundation, Targovax is dedicated to addressing unmet medical needs in oncology.
Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for haematological cancers. The company’s lead product candidate is Betalutin, an antibody-radionuclide-conjugate, which has completed Phase I/IIa clinical trial for the treatment of patients with non-hodgkin lymphoma, a life-threatening blood cancer. Nordic Nanovector ASA has collaboration agreements with Paul Scherrer Institute; Areva Med; LegoChemBio; and Heidelberg Pharma. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was founded in 2009 and is headquartered in Oslo, Norway.
Nextera AS is a drug discovery company based in Oslo, Norway, specializing in the development of therapies for autoimmune diseases and other major disease classes, including chronic infections and cancer. Founded in 2009, the company utilizes advanced phage display technology to identify new drug targets and enhance the discovery of potential drug candidates. Its innovative platforms, including taggerphage and DeltaPhage technologies, improve the efficiency and stability of drug candidate discovery. Nextera also emphasizes the integration of companion diagnostics with its therapeutic leads, ensuring effective treatment tailored to specific disease mechanisms. By focusing on high-resolution target discovery and lead candidate development, Nextera aims to provide improved therapeutic efficacy while minimizing off-target side effects.